Sex-specific survival benefit in early skin melanoma based on 8th AJCC edition: an analysis of data from the Surveillance, Epidemiology, and End Results (SEER) database.

BACKGROUND: Females have been found to have a survival benefit over males in past studies. However, in early melanoma patients, this benefit occurred in only those aged >60 years. The 8th edition of the American Joint Committee on Cancer (AJCC) readjusted the melanoma staging system, specifically stage I. This study aims to verify whether the sex-specific benefit in females exists in different age groups according to the 8th edition of the staging system.
METHODS: We collected the data of individuals diagnosed with skin melanoma between 2004 and 2015 from the Surveillance, Epidemiology, and End Results (SEER) database. Based on the 8th edition of the melanoma staging system, patients diagnosed with pathological stage T1a-T3a, N0 and M0 melanoma were enrolled.
RESULTS: A total of 115,576 patients, including 62,938 male patients and 52,638 female patients, were enrolled in this study. The survival rates of males and females in each stage from IA-IIA were significantly different (P<0.001). In further analyses of each age group, it was found that the proportions of patients with stages IA, IB and IIA were significantly different in each age group. Cox analysis showed that females with stage IA in all age groups benefited significantly, but those in stage IB benefited only when they were aged >60 years. In stage IIA patients, there were significant differences between the <50 and 61-70 years age groups.
CONCLUSIONS: Based on data from the SEER database, we found that according to the 8th edition of the AJCC melanoma staging system, females had a higher survival rate than males, and this difference was significant in all age groups in the stage IA group but fluctuated with age in the stage IB and IIA groups. 2021 Annals of Translational Medicine. All rights reserved.

Introduction

In October 2016, the 8th edition of the melanoma staging system was published, and the system was officially implemented on January 1, 2018 (1). In this edition, an important adjustment was made, which refined the T1 stage; for the first time, the new system considers a thickness of 0.8 mm as a separation indicator (). Previous American Joint Committee on Cancer (AJCC) staging manuals have recommended that the melanoma tumour thickness should be accurate to 0.01 mm (2,3). However, considering the accuracy of measurement, especially the thickness of tumours in paraffin sections, is difficult to obtain an accuracy of 0.01 mm. In the 8th edition, this accuracy value was eliminated and adjusted to 0.1 mm. Tumours with thicknesses of 0.75–0.84 mm are collectively considered 0.8 mm, and tumours with thicknesses of 0.95–1.04 mm are considered 1.0 mm. Furthermore, the definition of T1 has also been adjusted. Although the mitotic rate is still considered to be an independent risk factor that may affect prognosis (4,5), it was abandoned as an indicator; in the 7th edition, it was used to differentiate T1a and T1b. Ulceration was re-added as a criterion for the T1 stage. These three changes have resulted in substantial changes to the classification of the T1 stage.

Table 1

6th, 7th and 8th edition of staging system in T1 category

	6th			7th			8th
	Thickness	Others		Thickness	Others		Thickness	Others
T1a	≤1.0 mm	Without ulceration and level II/III		≤1.0 mm	Without ulceration and mitosis <1/mm2		<0.8 mm	Without ulceration
T1b	≤1.0 mm	With ulceration and level IV/V		≤1.0 mm	With ulceration or mitosis ≥1/mm2		<0.8 mm	With ulceration
							0.8–1.0 mm	With or without ulceration

Another major change is the staging system. In previous editions, in N0M0 cases, T1b + T2a were regarded as stage IB, and T1a was regarded as stage IA (2,3). In the 8th edition, the stage representing early melanoma was adjusted, T1a + T1b were collectively included in stage IA, and T2a was separately treated as stage IB (). This change not only applies to melanoma but also applies to other tumours, such as oesophageal adenocarcinomas (6).

Figure 1

6th, 7th and 8th edition of staging system in early melanoma.

Female sex has been considered one of the most important prognostic factors affecting melanoma in previous studies (7,8). Multiple studies have found that females have a lower long-term melanoma mortality rate than men. However, this protective effect may be affected by age (9-11). Studies have found that before the age of menopause, the incidence melanoma located on the trunk is similar in males and females, but after menopause, the incidence in females declines significantly (12). Another study also found that in patients with stage I melanoma, the survival advantage in female patients in the 46- to 59-year-old group was not significant, but in females over 60 years old, the survival advantage was obvious (10).

Considering that the 8th edition of the staging system readjusted the distribution and the definition of stage T1, we used malignant melanoma data from the SEER database to specifically quantify the effects of sex on early malignant melanoma in different age groups and observe whether a sex advantage could be observed in all age groups. We present the following article in accordance with the STROBE reporting checklist (Available at http://dx.doi.org/10.21037/atm-20-3845).

Methods

Patients were selected from the SEER database. The current SEER database is a population-based cancer registry sponsored by the National Cancer Institute, covering approximately 34.6% of the U.S. population. Every researcher has access to it (https://seer.cancer.gov). We selected individuals diagnosed with skin melanoma between 2004 and 2015 because the baseline data of patients wasn’t complete before 2004. Based on the 8th edition of the melanoma staging system, patients diagnosed with pathological stages T1a-T3a, N0 and M0 were enrolled. Other enrolment criteria included participation in active follow-up and skin melanoma as the primary malignant tumour. Patients were excluded if diagnosed at autopsy or if the cause of death was unknown.

Baseline data, including patient information (age, sex), and melanoma characteristics (location, subtype, Clark class, Breslow thickness, mitotic rate, and ulceration) were obtained from the SEER database. We reclassified cases to match the 8th edition of the melanoma staging system according to melanoma characteristics above. In this study, overall survival (OS) and melanoma-specific survival (MSS), which were collected from the SEER database through December 31, 2015, were used to evaluate outcomes. OS and MSS were defined as the interval from diagnosis until death from any cause and as a result of melanoma, respectively.

The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Statistical analysis

We used one-way ANOVA with a multiple comparison post hoc test and a chi-square test to analyse all continuous and categorical variables with normal distributions. The Kruskal-Wallis test was used to analyse data with non-normal distributions after adjusting for multiple confounders. Kaplan-Meier survival curves were estimated and compared with the log-rank test. Cox regression analysis was used to calculate hazard ratios (HRs) and 95% CIs. Risk factors with a P value <0.1 in the univariate analysis and with great importance were selected for the multivariable analysis. A two-sided P value <0.05 was considered statistically significant. We used SPSS 24.0 (SPSS, Chicago, IL, USA) and GraphPad Prism 7.0 (GraphPad Software, San Diego, CA, USA) for the analyses. The current study was approved by the ethics committee of Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, the Affiliated Hospital of Nanjing University Medical School (2017-175-01).

Results

A total of 115,576 patients were enrolled in the study. Among them, 62,938 were male and 52,638 were female (). In each age group, the number of patients is basically similar, respectively 37,149 cases (≤50 years age group), 26,847 cases (51–60 years age group), 25,237 cases (61–70 years old group), and 26,343 cases (>70 years age group). We conducted a comprehensive analysis of tumor stage, location, pathological subtype, Clark grade, mitotic rate and ulceration. In the comparison of men and women in each group, there was no significant difference in the distribution of T category and stage in the >70 years age group, while all other groups had significant differences (P<0.001). The distribution of tumors was significantly different in all groups (P<0.001). Among them, males had more cases on the trunk (41.2%), while females had a higher incidence of lower limbs (30.4%). In terms of pathological subtypes, males have more Lentigo maligna melanoma than normal type melanoma and Superficial spreading, while females have more Acral lentiginous than males. Clark grades were significantly different except for the >70 years age group (P=0.179). Although there was no significant difference in mitotic rate among overall patients group, there were significant differences in all age groups except the 61–70 years age group (P=0.255). There was no significant difference between the 61–70 years age group (P=0.638) and in the >70-year-old group (P=0.497).

Table 2

Baseline data in skin melanoma patients

	All patients (n=115,576)				≤50 years age group (n=37,149)				51–60 years age group (n=26,847)				61–70 years age group (n=25,237)				>70 years age group (n=26,343)
	Male (n=62,938)	Female (n=52,638)	P value		Male (n=15,291)	Female (n=21,858)	P value		Male (n=15,227)	Female (n=11,620)	P value		Male (n=15,995)	Female (n=9,242)	P value		Male (n=16,425)	Female (n=9,918)	P value
Stage
IA	48,606 (77.2%)	42,482 (80.7%)	<0.001		12,185 (79.7%)	18,364 (84.0%)	<0.001		11,969 (78.6%)	9,545 (82.1%)	<0.001		12,470 (78.0%)	7,415	<0.001		11,982 (73.0%)	7,158 (72.2%)	0.179
IB	8,849 (14.1%)	6,517 (12.4%)			2,095 (13.7%)	2,470 (11.3%)			2,149 (14.1%)	1,385 (11.9%)			2,183 (13.6%)	1,155			2,422 (14.7%)	1,507 (15.2%)
IIA	5,483 (8.7%)	3,639 (6.9%)			1,011 (6.6%)	1,024 (4.7%)			1,109 (7.3%)	690 (5.9%)			1,342 (8.4%)	672			2,021 (12.3%)	1,253 (12.6%)
T category
T1a	42,177 (67.0%)	37,324 (70.9%)	<0.001		10,583 (69.2%)	16,288 (74.5%)	<0.001		10,398 (68.3%)	8,404 (72.3%)	<0.001		10,905 (68.2%)	6,545 (70.8%)	<0.001		10,291 (62.7%)	6,087 (61.3%)	0.055
T2a	6,429 (10.2%)	5,158 (9.8%)			1,602 (10.5%)	2,076 (9.5%)			1,571 (10.3%)	1,141 (9.8%)			1,565 (9.8%)	870 (9.4%)			1,691 (10.3%)	1,071 (10.8%)
T3a	8,849 (14.1%)	6,517 (12.4%)			2,095 (13.7%)	2,470 (11.3%)			2,149 (14.1%)	1,385 (11.9%)			2,183 (13.6%)	1,155 (12.5%)			2,422 (14.7%)	1,507 (15.2%)
T4a	1,965 (3.1%)	1,360 (2.6%)			355 (2.3%)	366 (1.7%)			396 (2.6%)	289 (2.5%)			487 (3.0%)	277 (3.0%)			727 (4.4%)	448 (4.6%)
T5a	3,518 (5.6%)	2,259 (4.3%)			656 (4.3%)	658 (3.0%)			713 (4.7%)	401 (3.5%)			855 (5.3%)	395 (4.3%)			1,294 (7.9%)	805 (8.1%)
Location
Head and neck	15,614 (24.8%)	6,455 (12.3%)	<0.001		2,777 (18.2%)	1,808 (8.3%)	<0.001		2,929 (19.2%)	1,047 (9.0%)	<0.001		4,034 (25.2%)	1,225 (13.3%)	<0.001		5,874 (35.8%)	2,375 (23.4%)	<0.001
Trunk	25,923 (41.2%)	14,429 (27.4%)			7,104 (46.5%)	7,268 (33.3%)			6,939 (45.6%)	3,183 (27.4%)			6,497 (40.6%)	2,218 (24.0%)			5,383 (32.8%)	1,760 (17.8%)
Upper limb and shoulder	15,467 (24.6%)	15,618 (29.7%)			3,311 (21.7%)	5,429 (24.8%)			3,784 (24.9%)	3,724 (32.0%)			4,204 (26.3%)	3,160 (34.2%)			4,168 (25.4%)	3,305 (33.3%)
Lower limb and hip	5,749 (9.1%)	15,992 (30.4%)			2,056 (13.4%)	7,289 (33.3%)			1,529 (10.0%)	3,632 (31.3%)			1,218 (7.6%)	2,620 (28.3%)			546 (3.3%)	2,451 (24.8%)
Others	185 (0.3%)	144 (0.3%)			43 (0.3%)	64 (0.3%)			46 (0.3%)	34 (0.3%)			42 (0.3%)	19 (0.2%)			54 (0.3%)	27 (0.8%)
Subtype of melanoma
Superficial spreading	22,545 (35.8%)	20,998 (39.9%)	<0.001		6,619 (43.3%)	9,854 (45.1%)	0.188		5,847 (38.4%)	4,757 (40.9%)	0.078		5,372 (33.6%)	3,414 (36.9%)	0.004		4,707 (28.7%)	2,973 (30.0%)	0.511
Nodular	2,641 (4.2%)	1,906 (3.6%)			534 (3.5%)	639 (2.9%)			577 (3.8%)	399 (3.4%)			624 (3.9%)	328 (3.5%)			906 (5.5%)	540 (5.4%)
Lentigo maligna melanoma	5,641 (9.0%)	2,675 (5.1%)			424 (2.8%)	302 (1.4%)			1,015 (6.7%)	452 (3.9%)			1,749 (10.9%)	751 (8.1%)			2,453 (15.0%)	1,170 (11.8%)
Acral lentiginous	340 (0.5%)	522 (1.0%)			78 (0.5%)	155 (0.7%)			60 (0.4%)	112 (1.0%)			81 (0.6%)	107 (1.2%)			121 (0.7%)	148 (1.5%)
Others	2,246 (3.6%)	1,638 (3.1%)			496 (3.2%)	618 (2.8%)			484 (3.2%)	346 (3.0%)			536 (3.4%)	279 (3.0%)			730 (4.4%)	395 (4.0%)
Melanoma not specified	29,525 (46.9%)	24,899 (47.3%)			7,140 (46.7%)	10,290 (47.1%)			7,244 (47.6%)	5,554 (47.8%)			7,633 (47.7%)	4,363 (47.2%)			7,508 (45.7%)	4,692 (47.3%)
Clark class
II	23,078 (36.7%)	20,870 (39.6%)	<0.001		5,699 (37.3%)	9,257 (42.4%)	<0.001		5,771 (37.9%)	4,641 (39.9%)	0.002		5,948 (37.2%)	3,587 (38.8%)	0.001		5,660 (34.5%)	3,385 (34.1%)	0.179
III	15,800 (25.1%)	13,350 (25.4%)			4,286 (28.0%)	5,890 (27.0%)			3,917 (25.8%)	2,990 (25.7%)			3,823 (23.9%)	2,286 (24.7%)			3,774 (23.0%)	2,184 (22.0%)
IV	16,433 (26.1%)	12,365 (23.5%)			3,822 (25.0%)	4,659 (21.3%)			3,861 (25.4%)	2,643 (22.7%)			4,144 (25.9%)	2,187 (23.7%)			4,606 (28.0%)	2,876 (29.0%)
V	651 (1.0%)	449 (0.9%)			90 (0.6%)	81 (0.4%)			122 (0.8%)	64 (0.6%)			131 (0.8%)	87 (0.9%)			308 (1.9%)	217 (2.2%)
Others	6,976 (11.1%)	5,604 (10.6%)			1,394 (9.1%)	1,971 (9.0%)			1,556 (10.2%)	1,282 (11.0%)			1,949 (12.2%)	1,095 (11.8%)			2,077 (12.6%)	1,256 (12.7%)
Mitotic rate
<1	19,346 (30.7%)	16,140 (30.7%)	0.550		3,956 (25.9%)	6,175 (28.3%)	<0.001		4,534 (29.8%)	3,798 (32.7%)	<0.001		5,663 (35.4%)	3,267 (35.3%)	0.255		5,193 (31.6%)	2,900 (29.2%)	0.004
=1	5,249 (8.3%)	4,590 (8.7%)			1,249 (8.2%)	1,817 (8.3%)			1,322 (8.7%)	1,028 (8.8%)			1,377 (8.6%)	909 (9.8%)			1,301 (7.9%)	836 (8.4%)
≥2	6,563 (10.4%)	5,144 (9.8%)			1,351 (8.8%)	1,738 (8.0%)			1,520 (10.0%)	1,147 (9.9%)			1,722 (10.8%)	985 (10.7%)			1,970 (12.0%)	1,274 (12.8%)
Unknown	31,780 (50.5%)	26,764 (50.8%)			8,735 (57.1%)	12,128 (55.5%)			7,851 (51.6%)	5,647 (48.6%)			7,233 (45.2%)	4,081 (44.2%)			7,961 (48.5%)	4,908 (49.5%)
Ulceration
No	59,063 (93.8%)	49,812 (94.6%)	<0.001		14,557 (95.2%)	21,003 (96.1%)	<0.001		14,410 (94.6%)	11,065 (95.2%)	0.030		15,051 (94.1%)	8,683 (94.0%)	0.638		15,045 (91.6%)	9,061 (91.4%)	0.497
Yes	3,853 (6.1%)	2,811 (5.3%)			731 (4.8%)	652 (3.0%)			810 (5.3%)	551 (4.7%)			938 (5.9%)	557 (6.0%)			1,374 (8.4%)	851 (8.6%)
Unknown	22 (0.0%)	15 (0.0%)			3 (0.0%)	3 (0.0%)			7 (0.0%)	4 (0.0%)			6 (0.0%)	2 (0.0%)			6 (0.0%)	6 (0.0%)

In terms of long-term survival curves, the survival rates of males and females with stage IA–IIA melanoma were significantly different among the patients (P<0.001) (). In a further analysis of each age group, it was found that there were significant differences in each of the age groups for stage IA (T1a + T1b), stage IB (T2a) and stage IIA (T2b + T3a) (). Considering that in a previous study, the age-related survival advantage of females with stage I melanoma may have been related to the stage adjustment, we separately analysed those with grades T1a and T1b (). In only the 61–70 years age group with grade T1b (P=0.054) was there no difference between males and females. In all other groups, females still maintained a sex advantage.

Figure 2

Survival curve of MSS in all patients of different stages. MSS, melanoma-specific survival.

Figure 3

Survival curve of MSS in stage IA patients in different ages groups. MSS, melanoma-specific survival.

Figure 4

Survival curve of MSS in stage IB patients in different ages groups. MSS, melanoma-specific survival.

Figure 5

Survival curve of MSS in stage IIA patients in different ages groups. MSS, melanoma-specific survival.

Figure 6

Survival curve of MSS in T1aN0M0 patients in different ages groups. MSS, melanoma-specific survival.

Figure 7

Survival curve of MSS in T1bN0M0 patients in different ages groups. MSS, melanoma-specific survival.

In the Cox analysis, for each group, we conducted a separate analysis considering age and additional analyses after adding other factors for correction (). In all the patient groups, the data indicated a significant female survival advantage (P≤0.001). Each age group in the stage IA group had a female survival advantage. In the stage IB group, after correction, the ≤50 years age group (P=0.099, HR: 1.294, 95% CI: 0.953–1.758) and 51–60 years age group (P=0.522, HR: 1.109, 95% CI: 0.808–1.522) showed no significant differences in survival between males and females. However, the >60 years age group showed a female survival advantage. The situation in the stage IIA group was interesting; the 51–60 years age group (P=0.122, HR: 1.305, 95% CI: 0.931–1.831) and the >70 years age group (P=0.161, HR: 1.148, 95% CI: 0.947–1.392) showed no significant differences in survival, but there was a significant difference in the 61–70 years age group (P=0.009, HR: 1.481, 95% CI: 1.103–1.990). Besides, the survival curve trend () was similar and no crossing, and it meant the independent variable(sex) meets the requirement of proportional hazards assumption.

Table 3

Cox analyze of male vs. female according to age groups

Subgroups	Variables	N (male vs. female)	P value	HR	95% CI
All patients
≤50 years	Unadjusted	15291:21858	<0.001	1.924	1.646–2.248
	Location, Clark class, Mitotic rate and Ulceration		<0.001	1.436	1.223–1.686
51–60 years	Unadjusted	15227:11620	<0.001	1.723	1.451–2.046
	Location, Clark class, Mitotic rate and Ulceration		0.001	1.357	1.133–1.625
61–70 years	Unadjusted	15995:9242	<0.001	1.712	1.466–2.000
	Location, Clark class, Mitotic rate and Ulceration		<0.001	1.519	1.290–1.789
>70 years	Unadjusted	16425:9918	<0.001	1.243	1.121–1.378
	Location, Clark class, Mitotic rate and Ulceration		<0.001	1.258	1.128–1.404
Stage IA
≤50 years	Unadjusted	12185:18364	<0.001	1.812	1.437–2.285
	Location, Clark class, Mitotic rate and Ulceration		<0.001	1.371	1.079 - 1.741
51–60 years	Unadjusted	11969:9545	<0.001	1.793	1.368–2.349
	Location, Clark class, Mitotic rate and Ulceration		<0.001	1.527	1.146–2.034
61–70 years	Unadjusted	12470:7415	0.001	1.505	1.190–1.904
	Location, Clark class, Mitotic rate and Ulceration		0.009	1.390	1.085–1.781
>70 years	Unadjusted	11982:7158	0.010	1.219	1.048–1.418
	Location, Clark class, Mitotic rate and Ulceration		0.005	1.258	1.071–1.478
Stage IB
≤50 years	Unadjusted	2095:2470	0.003	1.571	1.164–2.119
	Location, Clark class, Mitotic rate and Ulceration		0.099	1.294	0.953–1.758
51–60 years	Unadjusted	2149:1385	0.023	1.429	1.051–1.943
	Location, Clark class, Mitotic rate and Ulceration		0.522	1.109	0.808–1.522
61–70 years	Unadjusted	2183:1155	<0.001	2.110	1.550–2.875
	Location, Clark class, Mitotic rate and Ulceration		0.001	1.731	1.254–2.390
>70 years	Unadjusted	2422:1507	0.002	1.426	1.140–1.784
	Location, Clark class, Mitotic rate and Ulceration		0.006	1.392	1.098–1.764
Stage IIA
≤50 years	Unadjusted	1011:1024	0.001	1.683	1.249–2.267
	Location, Clark class, Mitotic rate and Ulceration		0.012	1.487	1.093–2.023
51–60 years	Unadjusted	1109:690	0.019	1.473	1.066–2.035
	Location, Clark class, Mitotic rate and Ulceration		0.122	1.305	0.931–1.831
61–70 years	Unadjusted	1342:672	0.006	1.480	1.119–1.958
	Location, Clark class, Mitotic rate and Ulceration		0.009	1.481	1.103–1.990
>70 years	Unadjusted	2021:1253	0.054	1.195	0.997–1.434
	Location, Clark class, Mitotic rate and Ulceration		0.161	1.148	0.947–1.392

Discussion

Based on the 8th edition of the AJCC malignant tumour staging system, we observed many changes in the different types of tumours, but these changes were not precise. A study found that in the 8th edition of the TNM staging for oesophageal adenocarcinoma, after adjusting for the new IA stage, better resolution than the 7th edition was not obtained (6). For early skin melanoma, a thickness of 0.8 cm was introduced, and the factors indicative of stage I melanoma was redistributed. Although neither sex nor age are factors that need to be considered in AJCC staging, we found that in early malignant melanoma patients, under the new staging system, in stage I patients, females had significant survival advantages in the different age groups, suggesting that the 8th edition of the staging system may show better differentiation than previous editions. In a further analysis of T1a and T1b patients, we found that only the 61–70 years age subgroup of the T1b group presented differences between males and females, with values slightly lower than the critical value (P=0.054), further demonstrating good performance of the new staging system.

The advantage of female sex in malignant melanoma is very significant, but this phenomenon is not unique to malignant melanoma. In breast cancer, the incidence rates before and after menopause also change significantly (12). Some studies believe that this may be related to oestrogen, but there is currently no strong evidence for this theory. The change in survival advantage with age has not been clearly explained. Some studies have found that the female survival advantage in melanoma patients is lost during pregnancy, but females in the postpartum period regain their survival advantage (7). This verifies the relevance of sex hormones. Some studies have suggested that oestrogen increases the number of melanocytes and regulates melanin concentration (13). Some genetic studies have also found that mutations in the melanocortin receptor (MC1R) regulate and improve survival in females. The goal is to enhance DNA repair and antioxidant capacity, and oestrogen can mediate oxidative stress and promote the induction of a response. Reactive oxygen species (ROS) are produced, which leads to cell death (14); therefore, the incidence of melanoma in females before and after menopause will be increased. However, these factors do not fully explain the effect of age on female survival advantage, and further research is still needed to verify the role of sex hormones in malignant melanoma.

In our study, the Cox analysis found that in the stage IB group, the phenomenon of female survival advantage occurred only when the patients were >60 years old (although the survival curve was also significantly different for those under 60 years old), similar to previous results. Because in the 8th edition, the composition of stage IB was T2aN0M0, the number of patients in the T2 stage was the same as those in the T2 stage in the 6th edition and the 7th edition. However, due to the redistribution of the T1 stage, the number of patients was completely different from the number of patients in the 6th and 7th editions. Therefore, in the IA group according to the new classification, which comprises T1a + T1b, we did not observe a female survival advantage that changed with age. This also further illustrates the rationality of the 8th edition and the redistribution of T1 stage indicators.

This sex-specific advantage changed slightly in the stage IIA group. We found that although the survival curves still showed differences, after adjusting for tumour location, Clark grade, mitotic rate, and ulceration, in the 51–60 years age group (HR: 1.305, 95% CI: 0.931–1.831) and in the 70 years age group (HR: 1.161, 95% CI: 0.947–1.392), there were no significant differences between sexes according to the Cox analysis. One possible explanation is that there were fewer patients in these groups than in other groups, affecting the result. However, these results also remind us that although factors other than thickness and ulceration have never been considered in previous stage IIA and T2 classifications, factors such as the Clark grade, mitotic rate, and tumour location may still affect the final survival outcome. Further analyses should be conducted in the future to clarify the specific impact of these factors on patients with stage IIA melanoma.

Although some studies have indicated that the female survival advantage was a result of biology (15,16), lifestyle is also one an important factor that could lead to an advantage. Since ultraviolet (UV) exposure is a clear cause of malignant melanoma (17,18), many studies have suggested that women's clothing styles and frequent usage of sunscreen may be protective factors, which explains why females are far less likely than males to develop malignant melanoma on the trunk (19,20). In Australia and European countries, the mortality rates of melanoma are higher than those in East Asian countries. In addition to skin colour, people in these countries engage in sunbathing, and exposure to environmental UV light may be important factor that affects the morbidity rate and prognosis (21). Moreover, males are more likely to engage in outdoor work and sports, and they have higher rates of smoking, drinking and drug use than females, all of which may lead to a decrease in survival (19).

Our study has some limitations. First, patients in this study were all from the United States, and previous research has shown that race, nationality and even latitude can significantly impact MSS. Second, the therapeutic regimen was not included in the survival analysis, which may also affect the results.

Conclusions

In summary, we have demonstrated that among patients in the SEER database, male melanoma patients had a lower OS rate than female patients with the same melanoma stage based on the 8th edition of the AJCC staging system. This difference was significant in all age groups in the stage IA group but fluctuated with age in the stage IB and IIA groups. Clinicians should be aware of this difference when considering treatment, strengthen postoperative education and regularly follow patients.

The article’s supplementary files as